Analyst Price Target is $41.43
▲ +75.92% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for REGENXBIO in the last 3 months. The average price target is $41.43, with a high forecast of $61.00 and a low forecast of $14.00. The average price target represents a 75.92% upside from the last price of $23.55.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in REGENXBIO. This Buy consensus rating has held steady for over two years.
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.